Table 3.
Paclitaxel pharmacokinetic parameters from the basic and covariate (categorical and continous) population pharmacokinetic models.
| Basic model | Categorical relationship (final model) | Continuous relationship | |
|---|---|---|---|
| OBJF | 8727.003 | 8703.350 | 8680.895 |
| Parameters (value (SE%)) | |||
| CL changing with time* | |||
| Slope (θ2) (lh−2) | 9.35 (7.32) | 10.0 (7.92) | 9.66 (6.95) |
| Min CL (θ1) (lh−1) | 7.64 (12.2) | 8.48 (12.9) | 8.59 (29.9) |
| t50 (θ4) (h) | 8.76 (16.4) | 9.36 (28.2) | 7.27 (102) |
| γ1 (θ3) | 2.94 (23.5) | 2.68 (30.2) | 2.12 (95.3) |
| Effect of zosuquidar on paclitaxel CL | |||
| Decrease with LY Cmax>350(µgl−1) (%) | – | 25.2 (12.4) | – |
| Emax (lh−1) | – | – | 5.49 (43.5) |
| LY Cmax50 (µgl−1) | – | – | 328 (15.4) |
| γ2 | – | – | 9.18 (129) |
| V1 (l) | 7.93 (14.0) | 7.95 (13.8) | 8.38 (13.0) |
| V2 (l) | 198 (7.78) | 196 (7.81) | 194 (16.0) |
| Q2 (lh−1) | 11.1 (7.37) | 10.8 (9.35) | 11.2 (11.3) |
| Q3 (lh−1) | 6.57 (15.8) | 6.76 (16.4) | 6.35 (39.4) |
| V3(l) | 7.00 (15.4) | 7.51 (18.9) | 10.2 (164) |
| ω CL (%) | 27.2 (33.2) | 25.9 (29.7) | 24.8 (34.3) |
| ω CL-Q2 (%) | 32.6 (23.4) | 30.5 (23.2) | 29.6 (24.7) |
| ω Q2 (%) | 44.5 (28.0) | 43.7 (26.1) | 43.5 (37.0) |
| ω CL-V2 (%) | 29.3 (30.7) | 26.1 (38.4) | 24.2 (39.5) |
| ω Q2-V2 (%) | 40.7 (29.9) | 39.6 (29.2) | 37.5 (35.1) |
| ωV2 (%) | 43.7 (26.6) | 42.8 (26.0) | 40.9 (31.4) |
| ωV1 (%) | 38.5 (58.6) | 40.0 (52.4) | 41.7 (58.6) |
| ω IOV CL (%) | 20.9 (33.2) | 15.2 (53.9) | 16.1 (56.2) |
| ω IOV V1 (%) | 57.5 (39.6) | 54.5 (42.8) | 46.6 (47.9) |
| Residual variance (%) | 22.7 (7.75) | 22.9 (7.77) | 22.5 (8.00) |
*
During the infusion *postinfusion 
with INF the length of the infusion and time the time from the start of the infusion.